Abstract:Abstract Background Myasthenia gravis (MG) is the most prevalent autoimmune disorder affecting the neuromuscular junction. A rapid deterioration in respiratory muscle can lead to a myasthenic crisis (MC), which represents a life-threatening condition with high mortality in MG. Multiple CD4+ T subsets and hypercytokinemia have been identified in the peripheral pro-inflammatory milieu during the crisis. However, the pathogenesis is complicated due to the many types of cells involved, leaving the underlying mechanism largely unexplored. Methods We conducted single-cell transcriptomic and immune repertoire sequencing on 33,577 peripheral blood mononuclear cells (PBMCs) from two acetylcholine receptor antibody-positive (AChR +) MG patients during MC and again three months post-MC. We followed the Scanpy workflow for quality control, dimension reduction, and clustering of the single-cell data. Subsequently, we annotated high-resolution cell types utilizing transfer-learning models derived from publicly available single-cell immune datasets. RNA velocity calculations from unspliced and spliced mRNAs were applied to infer cellular state progression. We analyzed cell communication and MG-relevant cytokines and chemokines to identify potential inflammation initiators. Results We identified a unique subset of monocytes, termed monocytes 3 (FCGR3B+ monocytes), which exhibited significant differential expression of pro-inflammatory signaling pathways during and after the crisis. In line with the activated innate immune state indicated by MC, a high neutrophil–lymphocyte ratio (NLR) was confirmed in an additional 22 AChR + MC patients in subsequent hemogram analysis and was associated with MG-relevant clinical scores. Furthermore, oligoclonal expansions were identified in age-associated B cells exhibiting high autoimmune activity, and in CD4+ and CD8+ T cells demonstrating persistent T exhaustion. Conclusions In summary, our integrated analysis of single-cell transcriptomics and TCR/BCR sequencing has underscored the role of innate immune activation which is associated with hypercytokinemia in MC. The identification of a specific monocyte cluster that dominates the peripheral immune profile may provide some hints into the etiology and pathology of MC. However, future functional studies are required to explore causality.

Immune repertoire profiling in myasthenia gravis

B-cell Receptor Repertoire Sequencing: Deeper Digging into the Mechanisms and Clinical Aspects of Immune-Mediated Diseases

Non-neuronal cholinergic activity is potentiated in myasthenia gravis

The role of innate immunity in myasthenia gravis

The Intricate Dance of Non-Coding RNAs in Myasthenia Gravis Pathogenesis and Treatment

Single-cell RNA-Seq reveals transcriptional heterogeneity and immune subtypes associated with disease activity in human myasthenia gravis

B cells in the pathophysiology of myasthenia gravis

Stereotypic T cell receptor clonotypes in the thymus and peripheral blood of Myasthenia gravis patients

Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica

Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy

Basic Research And Clinical Application Of Immune Repertoire Sequencing

Myasthenia Gravis: T and B Cell Reactivities to the Β-Bungarotoxin Binding Protein Presynaptic Membrane Receptor

Augmentation Of Circulating Follicular Helper T Cells And Their Impact On Autoreactive B Cells In Myasthenia Gravis

Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis

Non-Coding RNAs in Myasthenia Gravis: From Immune Regulation to Personalized Medicine

Myasthenia gravis: Molecular mechanisms and promising therapeutic strategies

Myasthenia gravis: the future is here

Peripheral Immune Landscape for Hypercytokinemia in Myasthenic Crisis Utilizing Single-Cell Transcriptomics.

Advancements and prospects of novel biologicals for myasthenia gravis: toward personalized treatment based on autoantibody specificities

Decrease of CD4+CD25highFoxp3+ regulatory T cells and elevation of CD19+BAFF-R+ B cells and soluble ICAM-1 in myasthenia gravis

Distribution and Temporal Changes of Autoantibody-Mediated Pathogenic Mechanisms Among Acetylcholine Receptor-Positive Myasthenia Gravis Patients